NEW YORK and HILDEN,
Germany, June 3, 2017 /PRNewswire/ -- Bristol-Myers
Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt
Prime Standard: QIA) have signed an agreement to explore the use of
next-generation sequencing (NGS) technology to develop gene
expression profiles (GEPs) as predictive or prognostic tools for
use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies
in cancer treatment. This will leverage the combination of
Bristol-Myers Squibb's portfolio of I-O therapies with QIAGEN's
proven track record in developing and commercializing companion and
complementary diagnostics as well as QIAGEN's portfolio of NGS
technologies. I-O therapies offer a novel way to treat cancer by
using drugs to target the body's immune system to help fight
cancer.
QIAGEN and Bristol-Myers Squibb intend to develop GEPs for
several Bristol-Myers Squibb I-O molecules under the initial
agreement. The companies also plan to enter into a further
agreement to develop diagnostic products using the jointly
developed GEPs to expand the use of NGS technology with other
Bristol-Myers Squibb I-O therapies.
"Greater precision in the treatment of cancer may enable faster
decision making to identify which patient populations are most
likely to derive benefit from our immuno-oncology agents," said
Fouad Namouni, M.D., head of Development, Oncology, Bristol-Myers
Squibb. "We believe working with QIAGEN will help develop better
diagnostic tools to target the most appropriate immunotherapies
across a number of different tumor types."
Click here for full press release
https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={B0261CF5-83A7-4C91-9390-E5D5BC1DCCFF}&lang=en
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bristol-myers-squibb-and-qiagen-sign-agreement-for-use-of-ngs-technology-to-develop-gene-expression-profiles-for-immuno-oncology-therapies-300468294.html
SOURCE QIAGEN